looks like the chart opens right up.... would assume these patients are the "subset" that is of the "most interest" since they are probably the ECOG 0/1 patients with probability of having a stronger immune system at time of taking Bavi... allowing their immune system to have the "greatest chance of immune response".
MOS is clearly resolved but there are still quite a few ticks on the KM curve for pancreatic. Too bad they never seem to revisit the data later when more of these are resolved and the extended survival data is hopefully indisputable.